Shirley Clayton, MBA, Stanford School of Business, was involved in early financing of the biotechnology industry at Genentech as VP and Treasurer in the early 1980s. She was CEO & President of Abmaxis (acquired by Merck &Co); CFO, Cybron, (acquired by GE Medical Systems); CFO, Orquest;
President & CEO, Topometrix Corp. (acquired by Thermo Instruments); CFO, Cygnus; CFO, Protein Design Labs; President and Co-founder, Raven Biotechnologies

Bob Dunkle, MBA, Strategic Business Development
Bob has more than 20 years experience leading life sciences companies, including CEO and VP positions.  Bob serves as Entrepreneur-in-Residence at QB3 (UCSF incubator). 

Nancy Mize, PhD, 10+ years managing Drug Development teams; Consultant, Pacific BioDevelopment;
Director, Dept. Protein Bioinformatics, Hyseq; Preclinical development, Alza Corp;
Inventor of 11 issued patents, including 2 issued stem cell factor patents. BS, UC Berkeley;
PhD, UCSF; European Molecular Biology Laboratory (EMBL), and Genentech 

Ellen Curtis, MBA, Stanford Graduate School of Business, Strategic Marketing and Product Planning. 15+ years in dermatology & skin repair including Vivus, Onset Dermatologics, Valeant, Dow, Connectics, OrthoNeutrogena, Sangstat